Christopher A. Luckhurst

Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease

Roland W. Bürli, Christopher A. Luckhurst, Omar Aziz et al. · Journal of Medicinal Chemistry · 2013 · 149 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model

Tracy-Shi Zhang Fang, Yu Sun, Andrew C. Pearce et al. · Nature Communications · 2023 · 91 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors

Christopher A. Luckhurst, Perla Breccia, Andrew J. Stott et al. · ACS Medicinal Chemistry Letters · 2015 · 55 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

Cathepsin C Inhibitors: Property Optimization and Identification of a Clinical Candidate

Mark Furber, A.K. Tiden, Philip Gardiner et al. · Journal of Medicinal Chemistry · 2014 · 54 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor

Christopher A. Luckhurst, Omar Aziz, Vahri Beaumont et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 46 citations

Medicine, Medicinal Chemistry, Pharmacology +9